Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05513950
Other study ID # CLI-10067AA1-01
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date January 25, 2023
Est. completion date June 25, 2024

Study information

Verified date April 2024
Source Chiesi Farmaceutici S.p.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety of CHF10067 (the study drug) and any side effects that might be associated with it. In addition, the study will evaluate how much of the study drug gets into the bloodstream and how long the body takes to remove it. The body's immune response to the study drug will also be evaluated. The study may also evaluate the effect of the study drug on the level of a certain protein in the body. Chiesi is conducting this study on patients affected by idiopathic pulmonary fibrosis (IPF, a lung disease). Chiesi is doing this study to establish the doses suitable for future studies.


Description:

The principal aim of this study is to obtain safety and tolerability data when CHF10067 is administered intravenously as single ascending doses to subjects with IPF. This information, together with the pharmacokinetic (PK) and immunogenicity data, will help establish the doses suitable for future studies in subjects. The effect of CHF10067 on TG2 levels will also be investigated as an exploratory endpoint. A sequential group, single ascending dose design has been chosen for safety reasons because CHF10067 is in the early stages of clinical development and no data in the IPF population has been collected so far. In addition, sentinel dosing will be used so that in each cohort 2 subjects (1 CHF10067 and 1 placebo) will be dosed at least 24 hours before the remaining 6 subjects. The study will be double-blind and placebo-controlled to avoid bias in the collection and evaluation of data during its conduct. Placebo has been chosen as the comparison treatment to assess whether any observed effects are treatment-related or simply reflect the study conditions.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 24
Est. completion date June 25, 2024
Est. primary completion date June 25, 2024
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: - Subject's written informed consent obtained prior to any study-related procedure. - Males or females, of any race, aged = 40 years of age. - Body weight = 45 kg. - Diagnosis of IPF as defined by current American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines. Diagnosis of IPF must be within the past 5 years prior to enrolment, and in the opinion of the Investigator, has been stable for at least 3 months. - Subjects not receiving any IPF treatment (including subjects with previous use of antifibrotic treatment that has been stopped for at least 2 weeks prior to screening) or receiving well-tolerated standard of care approved treatments at a stable dose for at least 8 weeks prior to screening (nintedanib or pirfenidone) and it is anticipated the dose will remain unchanged throughout the study. - Forced vital capacity (FVC) = 50% of predicted and ratio of forced expiratory volume in the first second (FEV1)/FVC = 0.7 at screening. - Diffusing capacity of the lung for carbon monoxide (DLCO; corrected for haemoglobin) = 35% at screening. - Able to understand the study procedures and the risks involved. - Male and Female subjects following contraceptive requirements detailed in the study protocol. Exclusion Criteria: - History of lower respiratory tract infection within 4 weeks prior to screening and up to Day 1 of the study. - History of acute exacerbation of IPF within 3 months prior to screening and up to Day 1 of the study - Active diagnosis of lung cancer or a history of lung cancer. - Active cancer or a history of cancer (other than lung cancer) with less than 5 years disease free survival time (whether or not there is evidence of local recurrence or metastases). - Infiltrative lung disease other than IPF - Subjects exhibiting unhealed wounds or foot ulcers or have known history of wound healing complications. - Chronic heart failure categorized as New York Heart Association Class II, III, or IV; clinical diagnosis of cor pulmonale requiring specific treatment; or severe pulmonary hypertension - Currently receiving, or have received, a systemic corticosteroid, immunosuppressant, cytotoxic therapy, vasodilator therapy for pulmonary hypertension, or unapproved or investigational treatment for IPF within 4 weeks prior to screening or prior to randomization. - Coronavirus disease-2019 (COVID-19) vaccine at least 7 days before dosing. Any systemic symptoms (e.g. myalgia, fever, chills, fatigue, etc.) after COVID-19 vaccine should subside at least 2 days before the Day 1 visit. - Documented COVID-19 diagnosis within the last 4 weeks or which has not resolved within 7 days prior to screening or before treatment. - Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation or any other substance used in the study. - History of allergic or anaphylactic reaction to human, humanised, chimeric, immunoglobulins (Igs), or murine monoclonal antibodies. - Clinically relevant abnormal laboratory values (clinical chemistry and haematology) at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the subject or the evaluation of the study results according to Investigator judgement. . - Pregnant or lactating women.

Study Design


Intervention

Biological:
CHF10067 starting dose
Intravenous administration of a starting dose of the monoclonal antibody
CHF10067 intermediate dose
Intravenous administration of an intermediate dose of the monoclonal antibody
CHF10067 high dose
Intravenous administration of a high dose of the monoclonal antibody
Drug:
Placebo
Intravenous administration of a physiological solution as placebo.

Locations

Country Name City State
North Macedonia PHI University Clinic of Pulmonology and Allergology Skopje
Ukraine Medical Center of Limited Liability Company "Arensia Exploratory Medicine", department of Clinical Trials Kyiv
United Kingdom Queen Elizabeth Hospital - NIHR Birmingham Clinical Research Facility - University Hospitals Birmingham NHS Foundation Trust Birmingham
United Kingdom Royal Papworth Hospital NHSFT - Cambridge Biomedical Campus Cambridge
United Kingdom University of Dundee, NHS Tayside - Ninewells Hospital & Medical School Dundee
United Kingdom Interstitial Lung Disease Research - NHS Lothian - Royal Infirmary of Edinburgh, Edinburgh
United Kingdom Liverpool Clinical Research Facility - Liverpool University Hospital Foundation Trust Liverpool
United Kingdom Medicines Evaluation Unit - The Langley Building Manchester
United Kingdom University Hospital Southampton - Department of Respiratory Medicine Southampton

Sponsors (1)

Lead Sponsor Collaborator
Chiesi Farmaceutici S.p.A.

Countries where clinical trial is conducted

North Macedonia,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Transglutaminase 2 levels in plasma To evaluate Transglutaminase 2 levels in plasma changes from baseline over time will be described From predose up to 84 days post dose
Primary Adverse Event recording Adverse Event recording From pre-dose up to day 84
Secondary Systemic exposure (area under the concentration-time curve from zero to time) to CHF10067. To evaluate the area under the concentration-time curve from zero to the last quantifiable concentration (AUC0-t) of CHF10067 after a single dose. From pre-dose up to day 84
Secondary Area under the concentration-time curve from zero to infinity (AUC0-8) of CHF10067 To evaluate the area under the concentration-time curve from zero to infinity (AUC0-8) of CHF10067 after a single dose From pre-dose up to day 84
Secondary Maximum plasma concentration (Cmax) of CHF10067 To evaluate the Cmax (maximum observed concentration) after a single dose of CHF10067 From pre-dose up to day 84
Secondary Time to Cmax To evaluate the Time to Cmax (tmax) (time to maximum observed concentration) From pre-dose up to day 84
Secondary terminal half-life (t1/2) of CHF10067 To evaluate the Time to t1/2 of CHF10067 From pre-dose up to day 84
Secondary Evaluation of CHF10067 immunogenicity profile Evaluation of Anti Drug Antibodies and neutralising antibody (nAb) From predose up to 84 days post dose
Secondary Vital signs Systolic and diastolic blood pressure From pre-dose up to day 84
Secondary Oxygen saturation Oxygen saturation measured via pulse oximetry From pre-dose up to day 84
Secondary 12-lead ECG (Electrocardiogram) - HR The Heart Rate will be summarised using descriptive statistics at each analysis time point by treatment. From pre-dose up to day 84
Secondary 12-lead ECG (Electrocardiogram)-PR interval PR interval will be summarised using descriptive statistics at each analysis time point by treatment. From pre-dose up to day 84
Secondary 12-lead ECG (Electrocardiogram) - QRS interval QRS Interval will be summarised using descriptive statistics at each analysis time point by treatment. From pre-dose up to day 84
Secondary 12-lead ECG (Electrocardiogram) QTCF the number and percentage of subjects with abnormal actual QTCF (QT corrected for heart rate by Fridericia's formula) From pre-dose up to day 84
Secondary Spirometry FEV1 FEV1 (forced expiratory volume in the first second) parameters will be summarised using descriptive statistics at each analysis time point by treatment. From pre-dose up to day 84
Secondary Spirometry FVC FVC (forced vital capacity) parameters will be summarised using descriptive statistics at each analysis time point by treatment. From pre-dose up to day 84
Secondary Diffusing capacity (DLCO) Diffusing capacity (DLCO) parameters will be summarised using descriptive statistics at each analysis time point by treatment. From pre-dose up to day 84
Secondary Body temperature Body temperature will be monitored at screening, pre-dose, every 15 minutes during the infusion (e.g., 15, 30, 45, 60, 75, 90, 105, etc.), at the end of the infusion and 30 min, 1, 2, 3, 4, 6, 8, and 20 hours after the end of the infusion and 5, 7, 14, 28, 56, and 84 days post-dose
Secondary Pulse rate Pulse rate will be monitored At screening, pre-dose, every 15 minutes during the infusion (e.g., 15, 30, 45, 60, 75, 90, 105, etc.), at the end of the infusion and 30 min, 1, 2, 3, 4, 6, 8, and 20 hours after the end of the infusion and 5, 7, 14, 28, 56, and 84 days post-dose
Secondary Respiratory rate Respiratory rate will be monitored At screening, pre-dose, every 15 minutes during the infusion (e.g., 15, 30, 45, 60, 75, 90, 105, etc.), at the end of the infusion and 30 min, 1, 2, 3, 4, 6, 8, and 20 hours after the end of the infusion and 5, 7, 14, 28, 56, and 84 days post-dose
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05984992 - The First-in-human Study of SRN-001 in Healthy Participants Phase 1
Active, not recruiting NCT04312594 - Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT03865927 - GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03979430 - Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study N/A
Enrolling by invitation NCT04905693 - Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Phase 3
Not yet recruiting NCT06241560 - A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood Phase 2
Terminated NCT04419558 - Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 3
Completed NCT03725852 - A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Terminated NCT03573505 - An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT04148157 - Quality of Life in IPF - Patient and Physician Perceptions
Completed NCT03222648 - Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis N/A
Not yet recruiting NCT06422884 - A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) Phase 2
Completed NCT02257177 - RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients Phase 1/Phase 2
Completed NCT02268981 - Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF) N/A
Withdrawn NCT01524068 - A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations Phase 2
Enrolling by invitation NCT01382368 - Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Phase 4
Completed NCT01110694 - Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
Completed NCT01199887 - Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis Phase 1
Active, not recruiting NCT02951416 - Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
Terminated NCT00981747 - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Phase 2/Phase 3